Researchers have reported results from the first-ever clinical trial of a new class of targeted therapy in pet cats with head and neck squamous cell carcinoma (HNSCC)—a cancer which is notoriously deadly and difficult to treat. Publishing in the Cell Press journal Cancer Cell on August 28, the study found that 35% of the cats who received treatment had their disease controlled with minimal side effects—and the drug will likely be effective for humans with HNSCC as well. 

BUFFALO, NY — August 28, 2025 — A new research paper was published in Volume 12 of Oncoscience on July 31, 2025, titled “Burnout among oncology nurses and technicians in Morocco: Prevalence, risk factors, and structural equation modeling.”

A multi-institutional trial led by UNC Lineberger Comprehensive Cancer Center researchers found that a single infusion of autologous tumor-infiltrating lymphocyte (TIL) therapy stabilized metastatic head and neck squamous cell carcinoma in some patients who had not responded to multiple prior treatments. The study demonstrated the feasibility of consistently generating TILs from recurrent and or metastatic head and neck squamous cell carcinoma tumors to stabilize a patient’s disease.

In a new study published in the Proceedings of the National Academy of Sciences, University of Michigan researchers identified cellular features that determine whether tumor cells respond to treatment. 

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer, largely driven by mutations in the KRAS gene—once considered impossible to target.

Hong Kong Metropolitan University (HKMU) recently achieved its first-ever technology licensing agreement, a milestone in the University's efforts to translate research into impactful, real-world applications. A know-how licensing agreement for a non-invasive electrochemical screening technology, based on foundational research by Prof. A. L. Roy Vellaisamy, Chair Professor of Intelligent Systems in the School of Science and Technology, has been signed with a UK-based healthcare company. The technology offers a highly promising method for the early detection of prostate cancer through a simple urine test.

A recent survey commissioned by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) focused on Americans’ awareness of the signs and symptoms of prostate cancer. The survey results show most people (80%) don’t know early-stage prostate cancer often presents with no physical symptoms, typically only diagnosed with a blood test.